T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 5881-5890

  Chen, Su ^a   Jiao, Jian ^a   Jiang, Dongjie ^a   Wan, Zongmiao ^a   Li, Lei ^b   Li, Ke ^b   Xu, Leqin ^a   Zhou, Zhenhua ^a   Xu, Wei ^a   Xiao, Jianru ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Brachyury; Chemokine; Lung cancer; Macrophage infiltration

Indexed keywords

MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; T BOX TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR BRACHYURY; UNCLASSIFIED DRUG; BRACHYURY PROTEIN; CCL2 PROTEIN, HUMAN; CCL4 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; FETOPROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CELL INFILTRATION; CELL INVASION; COCULTURE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; LUNG TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOKINE CCL4; CHEMOKINE CXCL10; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MACROPHAGES; NEOPLASM INVASIVENESS; T-BOX DOMAIN PROTEINS;

EID: 84940438239     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3260-2     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? Future Oncol. 2014;10:417–28.
3. Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med. 2012;366:956–7.
4. Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40:558–66.
5. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007;127:514–25.
6. Ovchinnikov DA. Macrophages in the embryo and beyond: much more than just giant phagocytes. Genesis. 2008;46:447–62.
7. Mills CD. M1 and m2 macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32:463–88.
8. Deodhar AK, Rana RE. Surgical physiology of wound healing: a review. J Postgrad Med. 1997;43:52–6.
9. Greenhalgh DG. The role of apoptosis in wound healing. Int J Biochem Cell Biol. 1998;30:1019–30.
10. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585–601.
11. Papaioannou VE. T-box genes in development: from hydra to humans. Int Rev Cytol. 2001;207:1–70.
12. Tada M, Smith JC. T-targets: clues to understanding the functions of t-box proteins. Dev Growth Differ. 2001;43:1–11.
13. Dobrovolskaia-Zavadskaia N. Regarding the spontaneous mortification of the tail of a new-born mouse and the existence of a hereditary characteristic (factor). C R Seances Soc Biol Fil. 1927;97:114–6.
14. Wilkinson DG, Bhatt S, Herrmann BG. Expression pattern of the mouse t gene and its role in mesoderm formation. Nature. 1990;343:657–9.
15. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–98.
16. 16Li Y, Luo H, Liu T, Zacksenhaus E, Ben-David Y. The ets transcription factor fli-1 in development, cancer and disease. Oncogene. 2014.
17. Hsu I, Vitkus S, Da J, Yeh S. Role of oestrogen receptors in bladder cancer development. Nat Rev Urol. 2013;10:317–26.
18. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141:140–9.
19. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.
20. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-wide identification of pax3-fkhr binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010;70:6497–508.
21. Thoma C. Prostate cancer: Brachyury—a biomarker for progression and prognosis? Nat Rev Urol. 2014.
22. Pires MM, Aaronson SA. Brachyury: a new player in promoting breast cancer aggressiveness. J Natl Cancer Inst. 2014;106.
23. Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, et al. T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res. 2014.
24. Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. Overexpression of the emt driver brachyury in breast carcinomas: association with poor prognosis. J Natl Cancer Inst. 2014;106.
25. Kobayashi Y, Sugiura T, Imajyo I, Shimoda M, Ishii K, Akimoto N, et al. Knockdown of the t-box transcription factor brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: Implications for a new therapeutic principle. Int J Oncol. 2014;44:1107–17.
26. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 2012;18:3868–79.
27. Park JC, Chae YK, Son CH, Kim MS, Lee J, Ostrow K, et al. Epigenetic silencing of human t (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun. 2008;365:221–6.
28. Singer JB, Harbecke R, Kusch T, Reuter R, Lengyel JA. Drosophila brachyenteron regulates gene activity and morphogenesis in the gut. Development. 1996;122:3707–18.
29. Zheng J, Yang M, Shao J, Miao Y, Han J, Du J. Chemokine receptor cx3cr1 contributes to macrophage survival in tumor metastasis. Mol Cancer. 2013;12:141.
30. Iida N, Nakamoto Y, Baba T, Nakagawa H, Mizukoshi E, Naito M, et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of cc chemokine ligand 3/macrophage inflammatory protein-1alpha. Cancer Res. 2010;70:6556–65.
31. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, et al. The chemokine ccl2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009;11:1235–42.
32. Herrmann BG, Labeit S, Poustka A, King TR, Lehrach H. Cloning of the t gene required in mesoderm formation in the mouse. Nature. 1990;343:617–22.
33. Dobrovolskaia-Zavadskaia N. Brachyura, accompanying the bendings and the genetic structure of the tail of the mouse. C R Seances Soc Biol Fil. 1927;97:1583–5.
34. Yamada A, Koyanagi KO, Watanabe H. In silico and in vivo identification of the intermediate filament vimentin that is downregulated downstream of brachyury during xenopus embryogenesis. Gene. 2012;491:232–6.
35. Katikala L, Aihara H, Passamaneck YJ, Gazdoiu S, Jose-Edwards DS, Kugler JE, et al. Functional brachyury binding sites establish a temporal read-out of gene expression in the ciona notochord. PLoS Biol. 2013;11:e1001697.
36. Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer. 2011;47:1080–5.
37. Sarkar D, Shields B, Davies ML, Muller J, Wakeman JA. Brachyury confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer. 2012;130:328–37.
38. Pillay N, Plagnol V, Tarpey PS, Lobo SB, Presneau N, Szuhai K, et al. A common single-nucleotide variant in t is strongly associated with chordoma. Nat Genet. 2012;44:1185–7.
39. Kitamura Y, Sasaki H, Kimura T, Miwa T, Takahashi S, Kawase T, et al. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. J Neuropathol Exp Neurol. 2013;72:816–23.
40. Nibu Y, Jose-Edwards DS, Di Gregorio A. From notochord formation to hereditary chordoma: the many roles of brachyury. Biomed Res Int. 2013;2013:826435.
41. Barresi V, Ieni A, Branca G, Tuccari G. Brachyury: a diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers. Dis Markers. 2014;2014:514753.
42. Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M, Serra M, et al. Molecular profiling of chordoma. Int J Oncol. 2014;44:1041–55.
43. Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, et al. Expression of brachyury gene is a significant prognostic factor for primary lung carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S509–516.
44. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 2012;4:376–89.
45. Becker M, Muller CB, De Bastiani MA, Klamt F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol Histopathol. 2014;29:21–31.
46. El-Nikhely N, Larzabal L, Seeger W, Calvo A, Savai R. Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention. Expert Opin Investig Drugs. 2012;21:1107–22.